Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust
Eli Lilly’s high hopes for its IL-23 anti-inflammatory drug mirikizumab were borne out by a successful round of Phase III data demonstrating its superiority to Novartis’ IL-17 drug Cosentyx for psoriasis. But as is often the case, they’ve been beaten to the punch by rivals that have even (slightly) better numbers to boast about.
Looking at the PASI 90 score, a key measure on improvement in skin clearance from baseline, the late-stage drug hit PASI 90 scores of 81.4% and 82.4% at 52 weeks — compared to a mere 69.4% for the Novartis drug.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.